Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 148,600 shares, an increase of 7,330.0% from the November 30th total of 2,000 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily volume of 46,900 shares, the short-interest ratio is currently 3.2 days.
Alterity Therapeutics Trading Down 0.3 %
NASDAQ ATHE opened at $3.14 on Friday. Alterity Therapeutics has a 12-month low of $1.00 and a 12-month high of $3.37. The firm’s 50 day moving average is $1.60 and its 200-day moving average is $1.54.
Analysts Set New Price Targets
Separately, Maxim Group began coverage on Alterity Therapeutics in a report on Thursday, December 12th. They issued a “buy” rating and a $8.00 price target on the stock.
Alterity Therapeutics Company Profile
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.
Further Reading
- Five stocks we like better than Alterity Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- How Can Investors Benefit From After-Hours Trading
- How AI Implementation Could Help MongoDB Roar Back in 2025
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
